{"id":"W4386388190","doi":"10.1016/j.eururo.2023.08.010","title":"Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)]","year":2023,"lang":"en","type":"erratum","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Axitinib; Sunitinib; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Urology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002614186,0.001785138,0.002677892,0.002154395,0.001945363,0.0028167,0.002915101,0.007916375,0.07490696],"category_scores_gemma":[0.02405451,0.001044988,0.002854141,0.001796691,0.001026359,0.001372773,0.001122815,0.00907827,0.05053644],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004169946,"about_ca_system_score_gemma":0.005091635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03580274,"about_ca_topic_score_gemma":0.05442355,"domain_scores_codex":[0.9975943,0.0003949167,0.0004012418,0.0003610052,0.0009629753,0.0002854585],"domain_scores_gemma":[0.9888686,0.00355004,0.0007898143,0.0003575351,0.005427712,0.001006337],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002961468,0.000006375179,0.0000228393,0.00004058748,0.000006389751,0.0000620185,0.000002270915,0.00001324808,0.00001201472,0.00005575289,0.9978272,0.001921551],"study_design_scores_gemma":[0.0002684074,0.00008005279,0.001629041,0.0003462835,0.0000783922,0.0003153041,0.00002330167,0.0002171988,0.0001685572,0.0007142148,0.9961184,0.0000407968],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0001267602,0.003401379,0.0002601554,0.1344277,0.8483564,0.00009491584,0.002991178,0.0003489217,0.009992487],"genre_scores_gemma":[0.003708517,0.009458906,0.001107907,0.2905556,0.4449798,0.0003038021,0.004978193,0.0004602511,0.244447],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.07490696,"threshold_uncertainty_score":0.2505888,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05649958729501037,"score_gpt":0.3012588737262299,"score_spread":0.2447592864312195,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}